Novo Nordisk - ADR

Novo Nordisk - ADR

NVO

Market Cap$473.91B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novo Nordisk - ADRNovo Nordisk - ADR00.98%-1.8-

Earnings Call Q1 2024

May 3, 2024 - AI Summary

Novo Nordisk reported strong Q1 results with 24% sales growth and 30% operating profit growth.
The growth was driven by the GLP-1 portfolio, with a 32% increase in diabetes and a 42% increase in obesity.
Novo Nordisk continues to gain market share in diabetes, reaching 33%.

Exclusive for Stockcircle Pro members

Sign upSign Up
$159.67

Target Price by Analysts

21.4% upsideNovo Nordisk Target Price DetailsTarget Price
$155.04

Current Fair Value

17.9% upside

Undervalued by 17.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$473.91 Billion
Enterprise Value-
Dividend Yield$1.3644 (0.98%)
Earnings per Share$0.0
Beta0.6
Outstanding Shares3,390,128,000
Avg 30 Day Volume3,806,769

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio0.0
PEG0.0
Price to Sales1.83
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Novo Nordisk

CEO: Lars Fruergaard Joergensen